Proteasome inhibition prevents experimentally-induced endothelial dysfunction - PubMed (original) (raw)
. 2009 Jun 19;84(25-26):929-34.
doi: 10.1016/j.lfs.2009.04.016. Epub 2009 May 3.
Affiliations
- PMID: 19409913
- DOI: 10.1016/j.lfs.2009.04.016
Proteasome inhibition prevents experimentally-induced endothelial dysfunction
Mario Lorenz et al. Life Sci. 2009.
Abstract
Aims: We recently demonstrated that non-toxic inhibition of the proteasome upregulates antioxidative enzymes and leads to an adaptive transcriptional pattern in endothelial cells. We therefore hypothesized that proteasome inhibition could prevent experimentally-induced endothelial dysfunction. As there are conflicting data about the effects of proteasome inhibition on endothelial function, we investigated whether proteasome inhibition could prevent experimentally-induced endothelial dysfunction.
Main methods: Endothelial dysfunction in isolated rat aortic rings was induced by incubation of rings with TNFalpha for 48 h. To study the effects of the inhibition of the proteasome, selected rings were co-treated with proteasome inhibitors. Vasorelaxation and expression of genes involved in endothelial function were evaluated.
Key findings: Incubation of rat aortic rings with TNFalpha for 48 h led to significant dose-dependent reduction of acetylcholine-induced vasorelaxation. Co-incubation with TNFalpha and the proteasome inhibitor MG132 resulted in dose-dependent improvement of endothelium-dependent vasorelaxation in comparison to rings treated with TNFalpha alone. Levels of eNOS mRNA and protein were reduced despite improved vascular function after treatment with MG132. MG132 markedly suppressed mRNA levels of NADPH oxidase subunits and increased SOD1 expression. Superoxide production was reduced in rings incubated with MG132 in comparison to controls. TNFalpha-induced upregulation of the potent vasoconstrictor endothelin was abolished by MG132.
Significance: Proteasome inhibition prevents TNFalpha-induced vascular dysfunction by reduction of superoxide production and suppression of endothelin levels. The balance between vasoconstriction and vasodilatation is shifted in favour of endothelium-dependent vasodilation.
Similar articles
- Chronic administration of genistein improves endothelial dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity.
Vera R, Sánchez M, Galisteo M, Villar IC, Jimenez R, Zarzuelo A, Pérez-Vizcaíno F, Duarte J. Vera R, et al. Clin Sci (Lond). 2007 Feb;112(3):183-91. doi: 10.1042/CS20060185. Clin Sci (Lond). 2007. PMID: 17007611 - Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
Mondo CK, Yang WS, Zhang N, Huang TG. Mondo CK, et al. Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1029-34. doi: 10.1111/j.1440-1681.2006.04482.x. Clin Exp Pharmacol Physiol. 2006. PMID: 17042910 - Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine.
Ramzy D, Rao V, Tumiati LC, Xu N, Miriuka S, Delgado D, Ross HJ. Ramzy D, et al. Circulation. 2006 Jul 4;114(1 Suppl):I214-9. doi: 10.1161/CIRCULATIONAHA.105.000471. Circulation. 2006. PMID: 16820575 - The ubiquitin-proteasome pathway and endothelial (dys)function.
Stangl K, Stangl V. Stangl K, et al. Cardiovasc Res. 2010 Jan 15;85(2):281-90. doi: 10.1093/cvr/cvp315. Epub 2009 Sep 17. Cardiovasc Res. 2010. PMID: 19767293 Review. - Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?
Balakumar P, Chakkarwar VA, Krishan P, Singh M. Balakumar P, et al. Biomed Pharmacother. 2009 Mar;63(3):171-9. doi: 10.1016/j.biopha.2008.08.008. Epub 2008 Sep 27. Biomed Pharmacother. 2009. PMID: 18823739 Review.
Cited by
- Carfilzomib Mitigates Lipopolysaccharide/D-Galactosamine/Dimethylsulfoxide-Induced Acute Liver Failure in Mice.
Alhareth DY, Alanazi A, Alanazi WA, Ansari MA, Nagi MN, Ahmad SF, Attia MSM, Nadeem A, Bakheet SA, Attia SM. Alhareth DY, et al. Biomedicines. 2023 Nov 20;11(11):3098. doi: 10.3390/biomedicines11113098. Biomedicines. 2023. PMID: 38002097 Free PMC article. - Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review.
Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, Dimopoulos MA, Kastritis E, Stamatelopoulos K. Georgiopoulos G, et al. JACC CardioOncol. 2023 Feb 21;5(1):1-21. doi: 10.1016/j.jaccao.2022.12.005. eCollection 2023 Feb. JACC CardioOncol. 2023. PMID: 36875897 Free PMC article. Review. - Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.
Kastritis E, Laina A, Georgiopoulos G, Gavriatopoulou M, Papanagnou ED, Eleutherakis-Papaiakovou E, Fotiou D, Kanellias N, Dialoupi I, Makris N, Manios E, Migkou M, Roussou M, Kotsopoulou M, Stellos K, Terpos E, Trougakos IP, Stamatelopoulos K, Dimopoulos MA. Kastritis E, et al. Leukemia. 2021 May;35(5):1418-1427. doi: 10.1038/s41375-021-01141-4. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589757 Clinical Trial. - Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.
Fotiou D, Roussou M, Gakiopoulou C, Psimenou E, Gavriatopoulou M, Migkou M, Kanellias N, Dialoupi I, Eleutherakis-Papaiakovou E, Giannouli S, Delavinia C, Efstathiou K, Kontogiannis S, Terpos E, Dimopoulos MA, Kastritis E. Fotiou D, et al. Blood Cancer J. 2020 Nov 3;10(11):109. doi: 10.1038/s41408-020-00381-4. Blood Cancer J. 2020. PMID: 33149167 Free PMC article. Clinical Trial. - Role of the Ubiquitin Proteasome System in the Regulation of Blood Pressure: A Review.
Yamazaki O, Hirohama D, Ishizawa K, Shibata S. Yamazaki O, et al. Int J Mol Sci. 2020 Jul 28;21(15):5358. doi: 10.3390/ijms21155358. Int J Mol Sci. 2020. PMID: 32731518 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous